Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 5/20 | 0.51 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.50 |
| ▸ | PKN1 | Q16512 | 3/20 | 0.50 |
| ▸ | PAK4 | O96013 | 2/20 | 0.50 |
| ▸ | CDK4 | P11802 | 9/20 | 0.48 |
| ▸ | CCND1 | P24385 | 9/20 | 0.48 |
| ▸ | CCND2 | P30279 | 7/20 | 0.48 |
| ▸ | CCND3 | P30281 | 7/20 | 0.48 |
| ▸ | PAK3 | O75914 | 2/20 | 0.47 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.47 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.42 |
| ▸ | MARK3 | P27448 | 2/20 | 0.42 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.42 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.42 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 0.42 |
| ▸ | MARK1 | Q9P0L2 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986639 | 0.85 | WEE1 (0.51) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL11986702 | 0.84 | CDK4 (0.42) | WEE1CDK4CCND1CCND2CCND3 | |
| SCHEMBL4225865 | 0.83 | WEE1 (0.54) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL189156 | 0.83 | WEE1 (0.54) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL189169 | 0.82 | KDM4E (0.58) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL13236032 | 0.80 | ALDH1A1 (0.59) | CDK4CCND1CCND2CCND3PIK3CD | |
| SCHEMBL4216668 | 0.78 | WEE1 (0.47) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL188946 | 0.78 | WEE1 (0.47) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL188843 | 0.77 | PTK2 (0.50) | WEE1PAK1PKN1PAK4CDK4 | |
| SCHEMBL188479 | 0.76 | WEE1 (0.45) | WEE1PAK1PKN1PAK4CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | WEE1 358/4885PAK1 73/4885PKN1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.